According to FutureWise analysis, the market for human rotavirus vaccine in 2025 is US$ 8.04 billion, and is expected to reach US$ 14.57 billion by 2033 at a CAGR of 7.71%. The growth is fueled by the high global burden of rotavirus gastroenteritis in infants, along with strong support from national immunization programs. Increased vaccine coverage in low- and middle-income countries, along with backing from organizations like WHO and Gavi, is driving adoption. Improvements in vaccine formulations and cold-chain logistics also contribute to market growth.
Rotavirus is a highly contagious virus that primarily causes diarrhea. Before the introduction of a vaccine, it was common for children to experience at least one rotavirus infection by the age of five. Although rotavirus infections can be quite severe, many cases can be effectively managed at home with additional fluids to prevent dehydration. In instances of severe dehydration, hospitalization may be necessary, where patients can receive intravenous fluids.
Proper hygiene practices, particularly regular handwashing, play a crucial role in controlling the spread of the virus. However, immunization remains the most effective defense against rotavirus infection. Symptoms typically appear around two days after exposure to the virus, initially presenting as fever and vomiting, followed by watery diarrhea that can last from three to seven days. Abdominal pain may also be experienced.
While healthy adults may show little to no symptoms from a rotavirus infection, the virus can still be present in their stool up to ten days before symptoms arise and after they have resolved. This allows for rapid transmission through hand-to-mouth contact, even from asymptomatic individuals. Children under five years old are particularly vulnerable to severe diarrhea caused by rotavirus; however, this can be prevented through vaccination.
Vaccination not only protects young children but also contributes to lower rates of severe diarrhea across both developed and developing nations. It is essential in reducing child mortality rates associated with diarrhea. Furthermore, infant vaccination has been shown to decrease disease rates among older populations and individuals who are unvaccinated. The World Health Organization (WHO) advocates for the inclusion of the rotavirus vaccine in national routine vaccination programs, especially in areas where the virus is prevalent.
FutureWise Market Research has published a report that provides an insightful analysis of Human Rotavirus Vaccine Market trends that are affecting the overall market growth.

Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=9292&type=requestsample
Human Rotavirus Vaccine Market Segmentation:
By Type
• Rotarix
• Rotavac
• RotaTeq
• Rotavin-M1
• Lanzhou Lamb
• Others
By End User
• Hospitals
• Clinics
• Academic and Research Lab
• Others

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Human Rotavirus Vaccine Market:
• Biological E
• GlaxoSmithKline plc
• MerckCo.
• Bharat Biotech
• Lanzhou Institute of Biologicals Products Co. Ltd
• QIMR Berghofer Medical Research Institute
• BIOVIRx Inc
• Rixensart
• Emergent BioSolutions
• Astellas Pharma

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=9292&license=multi


**Objectives of this Study: **
1. To provide a comprehensive analysis of the Human Rotavirus Vaccine Market By Type, By End User and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: [email protected]

FutureWise Research
Contact Person: Vinay Thaploo.
Email: [email protected]
Contact Number: Asia: +91 8605575209 | UK: +44 0113 519 7222
Website: www.futurewiseresearch.com